ASAT

AskAt is a Japanese clinical-stage biotechnology company specializing in the development of small molecule drugs for high-need areas such as oncology, chronic pain, and neurodegeneration. Spun out from RaQualia Pharma in 2013, the company leverages a portfolio originally rooted in Pfizer’s research and development expertise. AskAt’s business model centers on a "networked partnering" strategy, where it identifies and develops promising candidates through early clinical stages before out-licensing them to global partners. Its lead human programs include EP4 antagonists for cancer and autoimmune disorders, as well as CB2 agonists for pain and dementia. The company is notably recognized for the global success of grapiprant in the veterinary market and is actively translating its prostaglandin and cannabinoid receptor expertise into human therapeutics.